Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan

Pediatrics International

Volumn 58, Issue 2, 2016, Pages 81-87

  Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

clinical study; rhabdomyosarcoma; treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MICRORNA; PAZOPANIB; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; EMBRYONAL RHABDOMYOSARCOMA; FAILURE FREE SURVIVAL; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INTERMEDIATE RISK POPULATION; JAPAN; LIVER VENOOCCLUSIVE DISEASE; LOW RISK POPULATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PEDIATRICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RHABDOMYOSARCOMA; UNITED STATES; CHILD; INFANT; MORTALITY; PRESCHOOL CHILD; RHABDOMYOSARCOMA, EMBRYONAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; JAPAN; PEDIATRICS; RHABDOMYOSARCOMA, EMBRYONAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84959573186     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12867     Document Type: Review

References (45)

1. Maurer HM, Beltangady M, Gehan EA, et al., The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61: 209-20.
2. Maurer HM, Gehan EA, Beltangady M, et al., The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71: 1904-22.
3. Crist W, Gehan EA, Ragab AH, et al., The Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 1995; 13: 610-30.
4. Crist WM, Anderson JR, Meza JL, et al., Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J. Clin. Oncol. 2001; 19: 3091-102.
5. Raney RB, Maurer HM, Anderson JR, et al., The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001; 5: 9-15.
6. Missiaglia E, Williamson D, Chisholm J, et al., PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012; 30: 1670-7.
7. Skapek SX, Anderson J, Barr FG, et al., PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report. Pediatr. Blood Cancer 2013; 60: 1411-7.
8. Hawkins DS, Spunt SL, Skapek SX, et al., Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas. Pediatr. Blood Cancer 2013; 60: 1001-8.
9. Arndt CA,. Risk stratification of rhabdomyosarcoma: A moving target. Am. Soc. Clin. Oncol. Educ. Book 2013; 415-9.
10. Arndt C, Hawkins D, Anderson JR, et al., Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J. Clin. Oncol. 2004; 22: 1894-901.
11. Ortega JA, Donaldson SS, Ivy SP, et al., Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer 1997; 79: 2435-9.
12. Heyn R, Raney RB Jr, Hays DM, et al., Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J. Clin. Oncol. 1992; 10: 614-23.
13. Paulino AC, Simon JH, Zhen W, et al., Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1489-95.
14. Raney RB, Anderson JR, Kollath J, et al., Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991. Med. Pediatr. Oncol. 2000; 34: 413-20.
15. Oberlin O, Rey A, Anderson J, et al., Treatment of orbital rhabdomyosarcoma: Survival and late effects of treatment-results of an international workshop. J. Clin. Oncol. 2001; 19: 197-204.
16. Paulino AC,. Late effects of radiotherapy for pediatric extremity sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60: 265-74.
17. Miyachi M, Kakazu N, Yagyu S, et al., Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res. 2009; 15: 4077-84.
18. Yoshida H, Miyachi M, Sakamoto K, et al., PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2014; 33: 5601-8.
19. Li G, Kikuchi K, Radka M, et al., IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment. Stem Cells 2013; 31: 2304-12.
20. Kikuchi K, Soundararajan A, Zarzabal LA, et al., Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2013; 32: 286-95.
21. Kikuchi K, Tsuchiya K, Otabe O, et al., Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2008; 365: 568-74.
22. Hosoi H, Dilling MB, Shikata T, et al., Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999; 59: 886-94.
23. Mayeenuddin LH, Yu Y, Kang Z, et al., Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene 2010; 29: 6367-77.
24. Kumar S, Mokhtari RB, Sheikh R, et al., Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 2011; 17: 5656-67.
25. Keir ST, Morton CL, Wu J, et al., Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2012; 59: 586-8.
26. Malempati S, Hawkins DS,. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr. Blood Cancer 2012; 59: 5-10.
27. Hosoi H, Teramukai S, Matsumoto Y, et al., A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int. J. Clin. Oncol. 2007; 12: 137-45.
28. Mansky P, Arai A, Stratton P, et al., Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr. Blood Cancer 2007; 48: 192-9.
29. Walterhouse D, Pappo AS, Meza JL, et al., Shorter duration therapy that includes vincristine (V), dactinomycin(A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). J. Clin. Oncol. 2011; 29: abstract 9516.
30. Walterhouse D, Pappo AS, Meza JL, et al., Vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). J. Clin. Oncol. 2012; 30: abstract 9509.
31. Arndt CA, Stoner JA, Hawkins DS, et al., Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803. J. Clin. Oncol. 2009; 27: 5182-8.
32. Meza JL, Anderson J, Pappo AS, et al., Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J. Clin. Oncol. 2006; 24: 3844-51.
33. Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al., Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: A report from the Children's Oncology Group. J. Clin. Oncol. 2011; 29: 1304-11.
34. Bradshaw-Pierce EL, Pitts TM, Kulikowski G, et al., Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 2013; 8: e58089.
35. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006; 6: 857-66.
36. Lu J, Getz G, Miska EA, et al., MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
37. Wei JS, Johansson P, Chen QR, et al., microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin. Cancer Res. 2009; 15: 5560-8.
38. Subramanian S, Lui WO, Lee CH, et al., MicroRNA expression signature of human sarcomas. Oncogene 2008; 27: 2015-26.
39. Ng EK, Chong WW, Jin H, et al., Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
40. Mitchell PS, Parkin RK, Kroh EM, et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 10513-8.
41. Lawrie CH, Gal S, Dunlop HM, et al., Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008; 141: 672-5.
42. Yamamoto Y, Kosaka N, Tanaka M, et al., MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009; 14: 529-38.
43. Miyachi M, Tsuchiya K, Yoshida H, et al., Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2010; 400: 89-93.
44. Miyachi M, Tsuchiya K, Hosoi H, et al., High serum miR-206 expression levels define an aggressive rhabdomyosarcoma subtype. Pediatr. Blood Cancer 2013; 60 (S3): S37.
45. Raney RB, Walterhouse DO, Meza JL, et al., Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011; 29: 1312-8.